TRCT
MBRX icon

Tower Research Capital (TRC)’s Moleculin Biotech MBRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.8K Buy
3,514
+1,679
+91% +$4.29K ﹤0.01% 4011
2026
Q1 		$4.2K Buy
1,835
+442
+32% +$1.46K ﹤0.01% 4224
2025
Q4 		$4.61K Buy
1,393
+1,058
+316% +$9.86K ﹤0.01% 4199
2025
Q3 		$4.44K Buy
335
+178
+113% +$2.4K ﹤0.01% 4349
2025
Q2 		$1.18K Buy
157
+103
+191% +$2.11K ﹤0.01% 4856
2025
Q1 		$1.31K Sell
54
-107
-66% -$3.6K ﹤0.01% 4740
2024
Q4 		$6.84K Buy
161
+89
+124% +$5.39K ﹤0.01% 4136
2024
Q3 		$5.14K Sell
72
-8
-10% -$577 ﹤0.01% 4322
2024
Q2 		$7.02K Buy
80
+55
+220% +$6.35K ﹤0.01% 4507
2024
Q1 		$3.67K Buy
25
+6
+32% +$1.28K ﹤0.01% 4822
2023
Q4 		$6.18K Sell
19
-19
-50% -$3.94K ﹤0.01% 4775
2023
Q3 		$6.12K Hold
38
– – ﹤0.01% 4642
2023
Q2 		$8.32K Buy
38
+5
+15% +$1.32K ﹤0.01% 4446
2023
Q1 		$12K Buy
33
+19
+136% +$8.32K ﹤0.01% 4097
2022
Q4 		$6K Sell
14
-12
-46% -$5.07K ﹤0.01% 4733
2022
Q3 		$10K Buy
26
+15
+136% +$8.69K ﹤0.01% 4546
2022
Q2 		$6K Hold
11
– – ﹤0.01% 4936
2022
Q1 		$7K Buy
+11
New +$6.31K ﹤0.01% 4737
2021
Q4 		– Hold
0
– – – 6381
2021
Q3 		– Sell
-7
Closed -$8.17K – 5998
2021
Q2 		$9K Buy
+7
New +$9.55K ﹤0.01% 4438
2021
Q1 		– Sell
-4
Closed -$7K – 5577
2020
Q4 		$7K Buy
+4
New +$7.1K ﹤0.01% 4496
2019
Q4 		– Hold
0
– -$1K – 4031
2019
Q3 		– Hold
0
– – – 3890
2017
Q2 		– Sell
-1
Closed -$4K – 3143
2017
Q1 		$4K Buy
+1
New +$3.5K ﹤0.01% 2324
2016
Q4 		– Hold
0
– – – 4172
2016
Q3 		– Sell
-1
Closed -$14.4K – 2559
2016
Q2 		$9K Buy
+1
New +$16.2K ﹤0.01% 2924

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Tower Research Capital (TRC)'s MBRX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Moleculin Biotech (MBRX) stake by 91% in Q2 2026, buying an estimated $4.29K and bringing the position to 3,514 shares worth $9.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4011.

Tower Research Capital (TRC) first reported a position in MBRX in Q2 2016 and has held it in 22 quarters since. The position peaked at $12K in Q1 2023. 11 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Tower Research Capital (TRC) held 3,514 shares of Moleculin Biotech worth $9.8K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,679 Moleculin Biotech shares in Q2 2026, an estimated $4.29K.
  • Moleculin Biotech made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4011 holding.
  • Tower Research Capital (TRC) first reported a position in Moleculin Biotech in Q2 2016 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s Moleculin Biotech position peaked at $12K in Q1 2023.
  • 11 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.